Want to see CMPX full AI Analyst Report?
CMPX Stock Chart & Stats
$2.43
$0.10(4.59%)
At close: 4:00 PM EDT
$2.43
$0.10(4.59%)
Day’s Range― - ―
52-Week Range$0.82 - $6.88
Previous CloseN/A
Volume336.06K
Average Volume (3M)5.83M
Market Cap
$154.88M
Enterprise Value$238.84M
Total Cash (Recent Filing)$179.88M
Total Debt (Recent Filing)$9.63M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding180,087,920
10 Day Avg. Volume5,519,184
30 Day Avg. Volume5,829,869
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap1.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-323.63
Enterprise Value/Ebitda-3.32
Forecast
1Y Price Target
$6.13Price Target Upside152.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPositive response and progression-free-survival results in a controlled study provide clinical validation for tovecimig and support its potential differentiation in a difficult cancer setting. If reproduced and accepted, these data can strengthen development and commercial prospects over the next several quarters.
Differentiated Lead AssetA first-in-class DLL4 x VEGF-A bispecific antibody gives Compass a differentiated lead asset, while Fast Track and Orphan Drug designations reflect an area of unmet need and may facilitate regulatory interaction. These attributes support a potentially defensible development position if efficacy and safety persist.
Low Financial LeverageLow debt relative to equity and substantial total assets provide financial flexibility compared with a highly leveraged biotech. This balance-sheet cushion can support continued pipeline development and reduce near-term solvency pressure, although it does not eliminate the need to fund ongoing operating losses.
Bears Say
Persistent Operating LossesVery limited revenue combined with large negative EBIT and net income shows that the company remains dependent on advancing clinical assets rather than operating commercialization. Continued losses reduce internal funding capacity and make future financial performance highly dependent on successful development outcomes.
Heavy Cash BurnSustained negative operating and free cash flow indicates that research and development spending currently consumes substantial cash without being offset by recurring operations. If this pattern continues, Compass will likely need additional external funding, creating dilution or financing pressure during pipeline development.
FDA Approval RiskThe FDA's request for another trial before a biologics application materially extends the pathway for the lead program and increases development uncertainty. It also raises the resources required to reach submission, while the lack of statistically significant overall-survival benefit weakens the current regulatory case.
Compass Therapeutics News
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $0.82 and its highest was $6.88 in the past 12 months.
What is Compass Therapeutics’s market cap?
Compass Therapeutics’s market cap is $154.88M.
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 23 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.019.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 180,087,920 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went up 5.291%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Currently, no hedge funds are holding shares in CMPX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compass Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.13 (152.06% Upside)
$6.13 (152.06% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 4.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $21.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.97%
12-Months-Change
Fundamentals
Return on Equity
-38.71%
Trailing 12-Months
Asset Growth
62.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Compass Therapeutics
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
CMPX Stock 12 Month Forecast
Average Price Target
$6.13
▲(152.06% Upside)
Technical Analysis
―
CytomX Therapeutics
―
Gossamer Bio
―
Bicycle Therapeutics
―
Monopar Therapeutics Inc
―
Ownership Overview
12.75% Insiders
7.09% Mutual Funds
<0.01% Other Institutional Investors
68.44% Public Companies and
Individual Investors